Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
Courtney D Di NardoCaitlin R RauschChristopher BentonTapan Mahendra KadiaNitin JainNaveen PemmarajuNaval G DaverWendy CovertKayleigh R MarxMorgan MaceElias J JabbourJorge CortesGuillermo Garcia-ManeroFarhad RavandiKapil N BhallaHagop M KantarjianMarina KonoplevaPublished in: American journal of hematology (2017)
Low-intensity chemotherapy, including HMAs or LDAC, in combination with VEN is a viable salvage option, even in multiply relapsed/refractory patients with AML, MDS, and BPDCN. Notable responses were identified in patients with diploid/intermediate cytogenetics, RUNX1, and/or IDH1/2 mutations.